Our results showed that TGFβRI and GSK3β are located upstream of NDRG1 in the signaling pathway and demonstrated that a combination of TGFβ and GSK3β inhibitors has the potential to reduce TNBC progression by impairing tumor initiation and ALDH1+ and CD44high/CD24- populations of CSCs. Here, NDRG1 is linked to neoplasm.